Bavarian Nordiv Research - Biotech IPO am NM - 500 Beiträge pro Seite

[Moon]

Hi Leute!

Ihr könnt diese Aktie jetzt schon kaufen!!!

Einige Facts:

WKN 917165
Marktcap. 100 Mio EUR (Konkurrent Medigene 600 Mio EUR)
Branche BIOTECH Wirkstoffforschung
Präparate: AIDS und KREBS in Ohase II!!! (und andere)
Mehr Infos unter www.bavarian-nordic.com und in Going-Public SOnderausgabe Biotech ("Die nächsten IPO´S)

Fazit jetzt schon kaufen!

[bondy]

Die Umsätzen ziehen sogar in Deutschland an!!

[Moon]

Und der Kurs auch!!
Viele Infos unter www.bavarian-nordic.com

[bondy]

NEUE PRESSEMITTEILUNG VON BAVARIAN NORDIC RESEARCH



Bavarian Nordic Research Institute A/S and Statens Serum Institute are to develop a broad-spectrum genetically based vaccine against HIV
Copenhagen, october 11, 2000



Bavarian Nordic Research Institute A/S and Statens Serum Institut have entered into a collaboration and licensing agreement for the development and marketing of a broad-spectrum genetically based vaccine against HIV.

Under the agreement, Bavarian Nordic has the option to world-wide exclusive licenses for the development, production and marketing of the HIV vaccine, as well as the unconditional right to licenses for other related inventions developed on the basis of the cooperation with Statens Serum Institut and Bavarian Nordic’s MVA vaccination system.

The agreement is based on the results of research carried out by Statens Serum Institut in cooperation with researchers at the University of Copenhagen and the Technical University of Denmark in the field of genetic vaccination with epitopes identified using novel computerized models. The vaccine epitopes are delivered by Bavarian Nordic’s MVA vector ensuring safe but potent immune induction.

Bavarian Nordic brings expertise in immunology, vaccine development, production and clinical trial management to the collaboration. The MVA vaccination system developed by Bavarian Nordic is ideally suited to be used in individuals whose immune system is impaired due to a viral infection or advanced cancer.

The new vaccine principle takes into account the great variation in the HIV virus and will trigger the patient’s cellular immune system, which is not normally activated by traditional vaccines, but which is essential for combating viral infections. The potential HIV vaccine will involve activation of the cellular immune system in order both to prevent and treat HIV infection, with or without combination with antiviral drugs.

"The collaborative effort represents Statens Serum Institut`s growing interest in the field of biotechnology and Bavarian Nordic`s expanding presence in the development of biotech products", says Nils Strandberg Pedersen, Chief Executive Officer of Statens Serum Institut.

"We are very pleased with the collaboration with Statens Serum Institut. In combination with other patented technologies available to Bavarian Nordic, the agreement will enhance Bavarian Nordic’s chances of developing a broadly applicable HIV vaccine", says Peter Wulff, Chief Executive Officer of Bavarian Nordic.

"Together with our promising MVA vaccination system, which is the world’s first MVA vaccination system approved for clinical trials in HIV patients, the Statens Serum Institut’s epitopes will be used with other novel inlicensed epitopes to create a strong portfolio of intellectual property within HIV vaccine development", concludes Peter Wulff.

Statens Serum Institut is a state-owned Danish enterprise engaged in medical research and the production and sales of among other things vaccines and plasma products.

Bavarian Nordic is a biopharmaceutical company listed on the Copenhagen Stock Exchange. The company specializes in the development of cell-based products and technologies as well as therapeutic vaccines for the treatment of serious diseases.

Asger Aamund
Chairman